Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25662192 | 1.00 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25660424 | 1.00 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25356880 | 0.96 | GRIK1 (0.42) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25356877 | 0.96 | GRIK1 (0.42) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL724270 | 0.94 | GRIK1 (0.44) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25662304 | 0.94 | GRIK1 (0.44) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL3447889 | 0.94 | GRIK1 (0.44) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL29855094 | 0.92 | PTGS1 (0.39) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25662323 | 0.83 | PRMT5 (0.35) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25660601 | 0.83 | PRMT5 (0.35) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | SLC1A3 2761/4885SLC1A2 4010/4885SLC1A1 3343/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | SLC1A3 2761/4885SLC1A2 4010/4885SLC1A1 3343/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | SLC1A3 2960/4885SLC1A2 4333/4885SLC1A1 3586/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | SLC1A3 2761/4885SLC1A2 4010/4885SLC1A1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.